Wall Street brokerages expect that Assembly Biosciences Inc (NASDAQ:ASMB) will report earnings per share of ($1.07) for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Assembly Biosciences’ earnings, with estimates ranging from ($1.15) to ($0.96). Assembly Biosciences reported earnings per share of ($0.80) in the same quarter last year, which would suggest a negative year over year growth rate of 33.8%. The company is expected to report its next earnings report on Monday, May 13th.
On average, analysts expect that Assembly Biosciences will report full-year earnings of ($4.37) per share for the current financial year, with EPS estimates ranging from ($5.19) to ($3.74). For the next year, analysts anticipate that the company will post earnings of ($5.33) per share, with EPS estimates ranging from ($5.80) to ($4.85). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover Assembly Biosciences.
Assembly Biosciences (NASDAQ:ASMB) last issued its quarterly earnings results on Thursday, February 28th. The biopharmaceutical company reported ($1.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.12). Assembly Biosciences had a negative net margin of 613.02% and a negative return on equity of 57.48%. The company had revenue of $3.74 million during the quarter, compared to the consensus estimate of $3.69 million.
Assembly Biosciences stock traded up $0.01 during mid-day trading on Friday, reaching $16.09. The company had a trading volume of 973 shares, compared to its average volume of 307,858. Assembly Biosciences has a 52 week low of $13.13 and a 52 week high of $48.91. The company has a market cap of $400.37 million, a PE ratio of -3.94 and a beta of 1.60.
Hedge funds have recently made changes to their positions in the stock. Tibra Equities Europe Ltd bought a new position in Assembly Biosciences during the 1st quarter valued at about $918,000. Man Group plc lifted its holdings in Assembly Biosciences by 19.6% during the 3rd quarter. Man Group plc now owns 36,042 shares of the biopharmaceutical company’s stock valued at $1,338,000 after purchasing an additional 5,904 shares during the last quarter. Marshall Wace LLP bought a new position in Assembly Biosciences during the 3rd quarter valued at about $11,224,000. Victory Capital Management Inc. lifted its holdings in Assembly Biosciences by 3.4% during the 4th quarter. Victory Capital Management Inc. now owns 530,909 shares of the biopharmaceutical company’s stock valued at $12,009,000 after purchasing an additional 17,669 shares during the last quarter. Finally, New York State Common Retirement Fund increased its position in Assembly Biosciences by 15.3% in the 4th quarter. New York State Common Retirement Fund now owns 23,300 shares of the biopharmaceutical company’s stock valued at $527,000 after acquiring an additional 3,100 shares in the last quarter. 83.74% of the stock is owned by hedge funds and other institutional investors.
About Assembly Biosciences
Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.
Recommended Story: Balanced Fund
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.